Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Instagram Outage Disrupts Thousands of U.S. Users 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CAMBRIDGE, Mass., Sept. 25, 2017 -- GO Therapeutics today announced that Salubris Pharmaceutical Limited has made a $5M investment in GO Therapeutics, a Cambridge, MA-based company exploiting new advances in glycoproteomics to develop novel, multimodal first-in-class cancer therapeutics against intractable targets.
The generation of solid tumor targeting domains that are specific to cancer cells remains a significant challenge in the drug development industry. GO Therapeutics' targeting platforms and technologies open a novel class of tumor-specific antigens that promise to realize the full potential of antibody-drug conjugates, bi-specific T-cell engagers, and immune-based cell therapies.
"This investment from Salubris will accelerate the development of our pre-clinical antibody programs, and help support the discovery of new antibodies against prioritized targets of interest. Additionally, Salubris offers future downstream market access to China, which is expected to become a significant consumer of innovative cancer therapies,” said Constantine Theodoropulos, Chief Executive Officer, GO Therapeutics.
“Novel, cancer-specific targets are imperative to widening the therapeutic window for powerful, cutting-edge cancer therapeutic modalities such as T-cell engagement and ADCs that offer tremendous promise for patients around the world. GO Therapeutics has the opportunity to generate significant value by opening an exciting new class of cancer-specific targets that will underpin transformative cancer therapies,” said Sam Murphy, VP and Head of International Business Development for Salubris, who will join GO Therapeutics’ board.
Salubris’ strategic investment extends the company’s expansion to the U.S. and evolution towards leading-edge innovations in oncology and cardiovascular disease. Earlier this year Salubris announced the opening of the SalubrisBio research facility outside of Washington D.C. where the focus is building the company’s internal portfolio of NME biologic product candidates (www.salubrisbio.com).
About GO Therapeutics
GO Therapeutics is applying the latest advances in glycobiology to create cancer drugs that are more potent and less toxic. GO Therapeutics’ cancer specific antibodies against tumor-specific antigens can be used in a multimodal approach to killing cancer, such as antibody-drug-conjugates, bi-specific T-cell engagers and immune-based cell therapies. The company’s scientific team includes some of the leading scientific researchers and applied biologists in glycoproteomics. GO Therapeutics is based in Cambridge, MA. For more information please visit www.gotherapeutics.com.
About Salubris Pharmaceutical Limited
Salubris Pharmaceutical Limited is a holding company of Shenzhen Salubris Pharmaceuticals Co., Ltd., a publicly-traded, fully-integrated pharmaceutical company [002294:CH]. Founded in 1998, Salubris has grown to achieve sales of >$750M USD in 2016. Salubris is headquartered in Shenzhen, China, and has over 3,800 employees working across R&D, regulatory, marketing and sales. Its marketed products include drugs and devices in the cardiovascular, anti-allergy and anti-infective therapeutic areas.
Constantine Theodoropulos 617-816-4637 [email protected]
